Showing results (301-310 of 494) with videos related to
Sort By:
Pageof 50
European Journal of Cancer (Oxford, England : 1990)|February 22, 2026
An updated European organization for research and treatment of cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for merkel cell carcinoma (MCC)Anna Szumera-Ciećkiewicz, Piotr Donizy, Thibault Kervarrec, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGISTAgnieszka Wozniak, Piotr Rutkowski, Patrick Schöffski, et al.The Lancet. Oncology|April 18, 2015
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trialJean-Yves Blay, Lin Shen, Yoon-Koo Kang, et al.Immunity|October 17, 2019
Transcriptional Atlas of Intestinal Immune Cells Reveals that Neuropeptide α-CGRP Modulates Group 2 Innate Lymphoid Cell ResponsesHeping Xu, Jiarui Ding, Caroline B M Porter, et al.Journal of Translational Medicine|May 10, 2022
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021Paolo A Ascierto, Allison Betof Warner, Christian Blank, et al.The Journal of Dermatological Treatment|May 31, 2021
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanomaBożena Cybulska-Stopa, Marcin Ziętek, Anna M Czarnecka, et al.Lancet (London, England)|June 15, 2020
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialRalf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, et al.Melanoma Research|April 4, 2023
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatmentBożena Cybulska-Stopa, Karolina Piejko, Krzysztof Ostaszewski, et al.European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trialPatrick Schöffski, Agnieszka Wozniak, Bernard Escudier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III TrialsDirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.Pageof 50